Baird Downgrades Synageva BioPharma (GEVA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Baird downgraded Synageva BioPharma (NASDAQ: GEVA) from Outperform to Neutral with a price target of $217.00 (from $115.00).
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Bank of India (BOI:IN) PT Lowered to INR150 at ICICI Securities
- Jefferies Upgrades Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
